This suggests GLP-1 receptor agonists may be particularly valuable in MHO individuals, whose arrhythmogenic risk may be driven more by obesity-related inflammation and fat distribution than by traditional metabolic pathways. The gene discussed is GLP1R; the disease is Obesity.